STIM · Neuronetics, Inc.
AI read · Neutral
The AI's read
Neuronetics guided 2026 revenue to $160M–$164M and said NeuroStar will move to broader ownership models. That points to a clear growth narrative if clinics adopt the new model and utilization rises. The market has already rallied hard, up +33.4% on the news, so much of the obvious upside looks baked in. RSI is only mid-50s, but the big pop reduces asymmetric upside from here. We lean neutral: guidance is constructive but the price action compressed the reward-to-risk ratio. We want concrete adoption and conversion metrics before increasing conviction.